Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botulinum toxin type A (Btx-A) Clear all
Completed No phase listed Observational

Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

NCT02557971
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Davis, California • Irvine, California • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain

NCT00178945
View directory record Official record
Conditions
Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS), Cervical Dystonia
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional

Music Therapy During Botulinum Injections

NCT00178217
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Music Therapy
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
1 Year to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 9, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain

NCT02221648
View directory record Official record
Conditions
Lower Back Pain
Interventions
Placebo, AbobotulinumtoxinA Treatment
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 9, 2026, 4:31 PM EDT
Not listed Phase 2 Interventional

Treatment of Hypertrophic Scars With Intradermal Botox

NCT03631368
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
Botox
Drug
Lead sponsor
Roy G. Geronemus, M.D.
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

NCT00660192
View directory record Official record
Conditions
Refractory Migraine
Interventions
Botox, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 9, 2026, 4:31 PM EDT
Not listed Not applicable Interventional

Optimal Injection Interval for Intra-Detrusor Botulinum Toxin

NCT06483217
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency, Urinary Incontinence, Urge Urinary Incontinence
Interventions
Patient-directed follow up
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01776606
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 9, 2026, 4:31 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Antibiotic Usage Prior to OnabotulinumtoxinA Injection

NCT04754737
View directory record Official record
Conditions
Antibiotic Stewardship, Overactive Bladder, Onabotulinumtoxin A, UTI
Interventions
No antibiotic, Prophylactic antibiotic, cystoscopic injection of onabotulinumtoxinA
Other · Procedure
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 9, 2026, 4:31 PM EDT
Not listed Phase 1 Interventional

New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain

NCT02008136
View directory record Official record
Conditions
Cervicalgia, Low Back Pain
Interventions
Botulinum Toxins
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population

NCT03055767
View directory record Official record
Conditions
Migraine Disorders, Headache, Migraine, Pediatrics
Interventions
OnabotulinumtoxinA, Placebo (Saline)
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
8 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

NCT00406367
View directory record Official record
Conditions
Blepharospasm
Interventions
incobotulinumtoxinA (Xeomin), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Botox in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder

NCT01350375
View directory record Official record
Conditions
Forward Head Posture With Associated Episodic Headache Disorder
Interventions
Botox, Saline
Drug
Lead sponsor
The Research Center of Southern California
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Brow Enhancement Study

NCT01308593
View directory record Official record
Conditions
Brow Ptosis
Interventions
Juvederm XC, Botox
Device · Drug
Lead sponsor
Skin Care and Laser Physicians of Beverly Hills
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 9, 2026, 4:31 PM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

NCT03569098
View directory record Official record
Conditions
Hallux Abducto Valgus
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 4 Interventional

A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction

NCT03199534
View directory record Official record
Conditions
Pelvic Pain, Dyspareunia, Pelvic Floor Dysfunction
Interventions
Botulinum toxin A 50u, Botulinum toxin A 100u, Botulinum toxin A 150u
Drug
Lead sponsor
EvergreenHealth
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 9, 2026, 4:31 PM EDT
Terminated Phase 4 Interventional Results available

BOTOX Effects on Seizure Severity and Susceptibility

NCT05605756
View directory record Official record
Conditions
Drug-resistant Focal Seizure
Interventions
OnabotulinumtoxinA 145 UNT [Botox]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 9, 2026, 4:31 PM EDT
Terminated Phase 1 Interventional

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

NCT05956509
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
ABBV-950, BOTOX, Placebo for ABBV-950
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
9
States / cities
Carlsbad, California • Downey, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

The Treatment of Depression With Botulinum Type A Toxin

NCT01392963
View directory record Official record
Conditions
Depression
Interventions
botulinum toxin type A neurotoxin complex, Placebo
Drug
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 9, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional

OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

NCT01920945
View directory record Official record
Conditions
New Daily Persistent Headache
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Upper Facial Remodeling With Perlane-L and Dysport

NCT01354743
View directory record Official record
Conditions
Mild to Moderate Temporal Atrophy, Moderate to Severe Glabellar Rhytids, Moderate to Severe Periorbital Rhytids
Interventions
Dysport, Perlane L
Drug · Device
Lead sponsor
Beer, Kenneth R., M.D., PA
Individual
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 9, 2026, 4:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014622
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 9, 2026, 4:31 PM EDT